Dublin, July 31, 2023 (GLOBE NEWSWIRE) -- The "Hemoglobinopathies Competitive Landscape and Market Forecast to 2027" report has been added to ResearchAndMarkets.com's offering. The Global ...

Hemoglobin disorders such as HbS and HbC affect millions of people worldwide. Countries around the world spend substantial resources each year identifying carriers, often relying on detailed ...

Hemoglobin is a protein found in the blood and a key oxygen transporter in the body. High hemoglobin levels have generally been considered desirable for a person's health. However, the latest research ...

Novartis AG NVS released detailed results from the Phase 3 APPOINT-PNH trial of investigational oral monotherapy iptacopan in complement-inhibitor-naïve (including anti-C5 therapies) adults with ...

AstraZeneca Plc (NASDAQ:AZN) released data from the Phase 3 ALPHA trial of danicopan as an add-on to the standard of care for paroxysmal nocturnal hemoglobinuria (PNH). The data showed that danicopan ...

The global COVID-19 pandemic has posed unique challenges for individuals with haemoglobin disorders, a group that includes sickle cell disease and thalassaemia. Although many patients experience mild ...

A series of laboratory studies is underway in the United States to improve gene therapy worldwide for sickle cell disease, a complex and sometimes deadly heritable blood disorder that dramatically ...

Novartis (NYSE:NVS) reported detailed results from a phase 3 trial of its oral drug iptacopan to treat certain patients with paroxysmal nocturnal hemoglobinuria (PNH). The study, dubbed APPOINT-PNH, ...

TAMPA, FL, UNITED STATES, April 30, 2026 /EINPresswire.com/ — San Rocco Therapeutics (SRT) today announced two abstracts at the upcoming 2026 ASGCT Annual Meeting ...

In neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Parkinson’s, and Alzheimer’s, healthy brain cells are damaged by aberrant reactive oxygen species (ROS). A potential ...

Adenosine base editing restarted fetal hemoglobin expression in cells from patients with sickle cell disease. Gene therapy that alters hemoglobin genes may be an answer to curing sickle cell disease ...